CD226 as a Genetic Adjuvant to Enhance Immune Efficacy Induced by Ag85A DNA Vaccination
Antigen-85A (Ag85A) is one of the major proteins secreted by Mycobacterium tuberculosis.Many studies on animal models have shown that vaccination with the recombinant Ag85A-DNA or Ag85A protein induces powerful immune response.However,these vaccines cannot induce sufficient protective immune response in the systemic compartment.CD226,a member of the immunoglobulin superfamily,is mainly expressed on NK cells,T cells,monocytes and platelets,and can be served as a co-stimulator that contributes to multiple innate and adaptive immune responses.GM-CSF is an effective genetic adjuvant that increases Ag85A immunogenicity to enhance the activity of cytotoxic T lymphocytes (CTLs) in mice immunized with recombinant pRSC-Ag85A-GM-CSF plasmid DNA.However,there has been no study showing that either CD226 protein or DNA has been used as an adjuvant for vaccine development.The aim of this study was to develop a novel Ag85A DNA vaccine with CD226 as the genetic adjuvant to increase the immune efficacy of Ag85A.Oral vaccination with pcDNA3.1- Ag85A-CD226 DNA induced potent immune responses in mice.CD226 was an effective genetic adjuvant that improved the immune efficacy of Ag85A and enhanced the activity of CTLs and NK cells in mice.Our results suggest that CD226 is an effective adjuvant to enhance the immune efficacy of Ag85A.Our findings provide a new strategy for the development of a DNA vaccine co-expressing Ag85A and CD226 against tuberculosis and tumors.
Ag85A CD226 genetic adjuvant DNA vaccine
Yan LI Xun SUN Changlong LU
Department of Immunology,China Medical University,Shenyang,110001,China;Department of Immunology and Department of Immunology,China Medical University,Shenyang,110001,China
国内会议
昆明
英文
1-13
2014-05-24（万方平台首次上网日期，不代表论文的发表时间）